Navigation Links
Martek Announces Fourth Quarter and FY 2010 Financial Results
Date:12/8/2010

rch and development 9,1716,93833,55727,448Selling, general and administrative  21,55712,02571,15548,083Advertising and promotion4,22859114,3001,944Amortization of intangible assets3,4831,47910,5056,389Acquisition costs111—3,583—Restructuring charge30,741—31,348—Other operating expenses9541241,4591,080Total operating expenses70,24521,157165,90784,944Income (loss) from operations(8,092)17,23350,84663,616Interest (expense) income and other, net(263)1(3,555)428Income (loss) before income tax provision(8,355)17,23447,29164,044Income tax provision (benefit)  (2,209)6,19519,39123,454Net income (loss)

$

(6,146)$

11,039$

27,900$

40,590Basic earnings (loss) per share

$

(0.18)$

0.33$

0.84$

1.22Diluted earnings (loss) per share

$

(0.18)$

0.33$

0.83$

1.22Shares used in computing basic earnings (loss) per share33,49033,25333,40433,207Shares used in computing diluted earnings (loss) per share33,49033,42433,57533,363Unaudited Condensed Consolidated Balance Sheets DataOctober 31,October 31, 20102009Assets:Cash and cash equivalents

$63,746$

141,063Short-term investments—7,301Accounts receivable, net69,56944,304Inventories, net93,976116,179Other current assets6,6955,240Property, plant and equipment, net221,770252,279Deferred tax asset9,42924,303Long-term investments4,9554,495Goodwill, intangibles and other long-term assets, net328,02194,653Total assets

$798,161$

689,817Liabilities and stockholders' equity:Accounts payable and accrued expenses

$52,517$

31,365Notes payable and other long-term obligations6,938810Deferred tax liability58,97810,091Deferred revenue8,74511,407Stockholders' equity670,983636,144Total liabilities and stockholders' equity

$798,161$

689,817Unaudited Condensed Consolidated Cash Flow DataYear ended October 31,20102009Operating activities:Net income

$

2
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Martek to Present at Upcoming Citi Small / Mid Cap Conference
2. Martek to Present at Upcoming UBS Conference
3. Martek Announces Third Quarter FY 2010 Financial Results
4. Martek Announces Fourth Quarter and FY 2009 Financial Results
5. Martek Signs Sole-Source Supply Agreement with Fonterra
6. Martek to Announce Fourth Quarter and Fiscal Year 2009 Results
7. Martek Announces Addition to Its Board of Directors
8. Martek to Present at Two Upcoming Investor Conferences
9. Martek Announces Settlement of Patent Dispute with Capsugel France
10. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
11. Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), ... GHS Label Guide . To align chemical container labeling with OSHA’s updated Hazard ... of label components, an example of an accurate label, and pictogram uses and ...
(Date:7/29/2015)... July 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... will be released on Thursday, August 13, 2015, before ... Pfenex management will host a conference call to discuss ... press release outlining the financial results and business update ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company, is pleased to announce that the final design ... been locked.  Prototypes for industrial and regulatory testing ... application for CE mark clearance to market the ... 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Brady Announces a New GHS Label Guide 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... March 21, 2011 Insmed Incorporated (Nasdaq: INSMD), a ... Drug Application (IND) to conduct a pivotal Phase 3 ... in nontuberculous mycobacteria (NTM) lung infections has been ...   In 2010, Insmed initially submitted a ...
... (LSE: SHP, Nasdaq: SHPGY ), the global ... alfa) in patients with Fabry disease, and VPRIV® (velaglucerase ... disease, at the 2011 American College of Medical Genetics, ... from March 16-20, 2011.   Data from ...
... 2011 Recent events in Japan have caused the ... radiation can be a cause for concern – especially ... targets rapidly proliferating cells of the body. Cells of ... tract are two such cell types. Damage to these ...
Cached Biology Technology:Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 2Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 3Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 4Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 5Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 2Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 3Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 4Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection) 5Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 3
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... is not coming from the biotech industry or ... children,s hospital. Nationwide Children,s Hospital in Columbus, ... have partnered to create BioLinQ, a new biomedical ... for disease diagnosis and medical research. "Years ...
... - People tend to think of ozone as something ... from UV radiation. At the ground level, however, ozone ... Lisa Ainsworth, a University of Illinois associate professor of ... biologist, said that establishing the exposure threshold for damage ...
... with partners In2Tec Ltd (UK) and Gwent Electronic Materials Ltd, ... be easily separated by immersion in hot water. The work ... government,s Technology Strategy Board. The Challenge ... 100 million electronic units are discarded annually in the UK ...
Cached Biology News:NCH partners with Silicon Valley to market high-end diagnostic and medical research software 2Ozone's impact on soybean yield: Reducing future losses 2Ozone's impact on soybean yield: Reducing future losses 3
Request Info...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: